Diffuse large B-cell lymphoma (DLBCL) research hub
9 indexed studies · 8 currently recruiting
- authorisedTherapeutic exploratory (Phase II)
HOVON 168: Epcoritamab in Addition to R-Mini-CHOP Compared to R-Mini-CHOP in Elderly, Frail or Unfit Patients with Diffuse Large B-cell Lymphoma
This study looks at a new drug combination for older or frail adults with diffuse large B-cell lymphoma, a type of blood cancer. Researchers want to see if adding an antibody drug called epcoritamab to standard, gentler chemotherapy helps clear the cancer better and keeps people well for longer.
Czechia · Denmark · Croatia - recruitingTherapeutic exploratory (Phase II)
A prospective multicenter phase 2 study of copanlisib in combination with rituximab and CHOP chemotherapy (COPA-R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL)
This study looks at a new drug, BAY 80-6946, with standard chemotherapy for a type of blood cancer called diffuse large B-cell lymphoma (DLBCL). It's in an early stage (Phase 2), focusing on finding the best dose and checking if the treatment is safe and effective.
Germany - recruitingPhase I and Phase II (Integrated)- First administration to humans
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
This study is testing a new medicine, GEN3014, for people with multiple myeloma or other blood cancers that have come back or not responded to previous treatments. It aims to see if the medicine is safe and how well it works.
Hungary · Spain · Czechia - recruitingPhase I and Phase II (Integrated)- Other
A Phase I/II Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Patients with Diffuse Large B-Cell Lymphoma following First-Line Immunochemotherapy and as Monotherapy or In Combination With Polatuzumab Vedotin in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
This study is looking at new ways to treat Diffuse Large B-Cell Lymphoma (DLBCL), a type of blood cancer. Researchers are testing a drug called mosunetuzumab, by itself or with another drug, polatuzumab vedotin. The aim is to see how well these treatments work and if they are safe.
Spain · Poland - not yet recruiting
The Microbiome in Blood Cancer and HLH
This study looks at how gut bacteria and viruses, called the microbiome, affect people with certain blood cancers and a severe inflammatory condition called HLH. Researchers want to better understand how these tiny organisms influence treatment response and side effects, aiming to improve future care.
United Kingdom - recruitingPHASE1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
This study is testing a new medicine, NX-5948, for adults with certain types of blood cancer that have come back or not responded well to previous treatments. It aims to find out if the medicine is safe and helps fight the cancer, starting with small doses and gradually increasing.
United States · France · Italy - recruitingPHASE1
A Study of NX-1607 in Adults With Advanced Malignancies
This study is looking into a new treatment called NX-1607 for various advanced cancers, including ovarian, stomach, and lung cancer. It aims to see how safe the treatment is and if it can help fight the cancer, sometimes combined with another drug called Paclitaxel.
United States · United Kingdom - recruitingPHASE3
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
This study compares a new drug, odronextamab, with standard treatment for a type of lymphoma called DLBCL. It looks at how well they work with chemotherapy and their safety in adults who haven't been treated before, or whose lymphoma has come back.
United States · Australia · Austria - recruitingPHASE1
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
This study is testing a new medicine called EXS73565 for people with certain types of B-cell cancers that have come back or not responded to usual treatments. We want to find a safe dose and see how it works.
Georgia · Greece · Moldova